Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?

Biomolecules

Stefania Di Mauro¹  Agnese Filippello¹  Salvatore Piro¹  Alessandra Scamporrino¹  Francesco Purrello¹  Alessio Mazzieri²  Francesca Porcellati²  Michelantonio De Fano²  Carmine Giuseppe Fanelli²  Roberta Malaguarnera³ 

[1] Department of Clinical and Experimental Medicine, Internal Medicine, Garibaldi-Nesima Hospital, University of Catania, 95122 Catania, Italy;Department of Medicine and Surgery, Perugia University School of Medicine, Via Gambuli 1, 06126 Perugia, Italy;Faculty of Medicine and Surgery, University of Enna “Kore”, 94100 Enna, Italy;

关键词: diabetes;    glucagon;    hypoglycemia;    therapy;   

DOI  :  10.3390/biom11091281

来源: DOAJ

【 摘 要 】

Hypoglycemia represents a dark and tormented side of diabetes mellitus therapy. Patients treated with insulin or drug inducing hypoglycemia, consider hypoglycemia as a harmful element, which leads to their resistance and lack of acceptance of the pathology and relative therapies. Severe hypoglycemia, in itself, is a risk for patients and relatives. The possibility to have novel strategies and scientific knowledge concerning hypoglycemia could represent an enormous benefit. Novel available glucagon formulations, even now, allow clinicians to deal with hypoglycemia differently with respect to past years. Novel scientific evidence leads to advances concerning physiopathological mechanisms that regulated glycemic homeostasis. In this review, we will try to show some of the important aspects of this field.

【 授权许可】

Unknown